Are active dwell positions always necessary in the ring/ovoids channel of the cervical applicator in the intracavitary-interstitial brachytherapy of cervical cancer?

被引:0
|
作者
Frohlich, Georgina [1 ,2 ]
Vizkeleti, Julia [1 ]
Nguyen, Anhhong Nhung [1 ]
Polgar, Csaba [1 ,3 ]
Takacsi-Nagy, Zoltan [1 ,3 ]
Major, Tibor [1 ,3 ]
机构
[1] Natl Inst Oncol, Ctr Radiotherapy, Budapest, Hungary
[2] Eotvos Lorand Univ, Dept Biophys, Fac Nat Sci, Budapest, Hungary
[3] Semmelweis Univ, Dept Oncol, Fac Med, Budapest, Hungary
关键词
cervical cancer; ring activation; ring applicator; Venezia applicator; interstitial brachytherapy; GUIDED ADAPTIVE BRACHYTHERAPY; SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA; RADIATION-THERAPY; AMERICAN BRACHYTHERAPY; MRI; RADIOTHERAPY; POINT; RECOMMENDATIONS; FEASIBILITY;
D O I
10.5114/jcb.2023.124399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare dosimetric parameters of brachytherapy (BT) treatment plans made with or without active source positions of the ring/ovoid (R/O) applicator in locally advanced cervical cancer patients. Material and methods: Sixty patients with cervical cancer without vaginal involvement were selected for the study, who received intra-cavitary/interstitial BT. For each patient, two plans with and without active source dwell positions in R/O were created, using the same dose-volume constraints. EQD2 total doses from external beam and BT of target volumes and organs at risk (OARs) between the competing plans were compared. Results: There was no significant difference in the dose of high-risk clinical target volume (HR-CTV) and gross tumor volume (GTV) between the plans with inactive vs. active R/O. The mean D98 of intermediate-risk clinical target volume (IR-CTV) was significantly lower with inactive R/O; however, the GEC-ESTRO (EMBRACE II study) and ABS criteria were fulfilled in 96% in both plans. There was no difference in dose homogeneity, but conformity of the plans with inactive R/O was higher. Doses to all OARs were significantly lower in plans without R/O activation. While all the plans without R/O activation fulfilled the recommended dose criteria for OARs, it was less achievable with R/O activation. Conclusions: Inactivation of R/O applicator results in similar dose coverage of the target volumes with lower doses to all OARs, as activation of R/O in cervix cancer patients when HR-CTV does not extend to R/O applicator. The use of active source positions in R/O shows worse performance regarding the fulfilment of the recommended criteria for OARs.
引用
收藏
页码:48 / 56
页数:9
相关论文
共 50 条
  • [21] The much-awaited Venezia applicator: virtues of combined intracavitary and interstitial brachytherapy in locally advanced cervical cancer
    Gangopadhyay, Aparna
    Saha, Subrata
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2018, 17 (04) : 460 - 461
  • [22] The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:: Design, application, treatment planning, and dosimetric results
    Kirisits, C
    Lang, S
    Dimopoulos, J
    Berger, D
    Georg, D
    Pötter, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (02): : 624 - 630
  • [23] Intracavitary/Interstitial Applicator Plus Distal Parametrial Free Needle Interstitial Brachytherapy in Locally Advanced Cervical Cancer: A Dosimetric Study
    Qu, Hong-Da
    Han, Dong-Mei
    Zhang, Ning
    Mao, Zhuang
    Cheng, Guang-Hui
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [24] Therapeutic Benefit of Intracavitary-interstitial Brachytherapy in Cervical Cancer Patients with Small and Large High-risk Clinical Target Volume
    Tambas, Makbule
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2021, 36 (04): : 431 - 437
  • [25] Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component
    Fokdal, Lars
    Tanderup, Kari
    Hokland, Steffen Bjerre
    Rohl, Lisbeth
    Pedersen, Erik Morre
    Nielsen, Soren Kynde
    Paludan, Merete
    Lindegaard, Jacob Christian
    RADIOTHERAPY AND ONCOLOGY, 2013, 107 (01) : 63 - 68
  • [26] Clinical Outcome Of High Dose Rate Combined Intracavitary/Interstitial Brachytherapy With The Ring Applicator In Locally Advanced Cervical Cancer: A Single Institutional Experience
    Cheng, G.
    Zhang, N.
    Zhao, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E490 - E490
  • [27] Combined MRI based intracavitary and interstitial brachytherapy for locally advanced cervical cancer with a modified tandem ring applicator -: Design, quality assurance and dosimetry
    Lang, S
    Dimopoulos, J
    Kirisits, C
    Bauer, N
    Wachter-Gerstner, N
    Wachter, S
    Georg, D
    Pötter, R
    RADIOTHERAPY AND ONCOLOGY, 2004, 71 : S72 - S73
  • [28] Active small bowel sparing in intracavitary brachytherapy for cervical cancer
    Goh, Youngmoon
    Kim, Dohyeon
    Kim, Joo-Young
    Kim, Hak Soo
    Jeong, Jong Hwi
    Lee, Sung Uk
    Youn, Sang Hee
    Oh, Eun Sang
    Ha, Bo Ram
    Yeo, Adam Unjin
    Kim, Myeongsoo
    Shin, Dongho
    Lee, Se Byeong
    Kim, Yeon-Joo
    Kim, Tae Hyun
    Lim, Young Kyung
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (03) : 266 - 273
  • [29] Combined intracavitary and interstitial brachytherapy in locally advanced cervical cancer.
    Piccolo, F.
    Pappalardi, B.
    Carrara, M.
    Tenconi, C.
    Giandini, T.
    Delle Curti, C.
    Fallai, C.
    Cerrotta, A.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S599 - S599
  • [30] Clinical outcome of intracavitary and interstitial brachytherapy in locally advanced cervical cancer
    Chitmanee, P.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S154 - S154